Loading organizations...
Orion Capital Partners is a commercial real estate investment and development firm. It specializes in acquiring, developing, and managing properties, employing strategic solutions for value maximization and growth across diverse asset classes such as office, healthcare, and industrial. The firm integrates value-add opportunities, ground-up development, and asset repositioning with local market expertise.
Co-founded in 2005 by Brock Martin, Ben Lester, and Burke Larkin, the firm leverages their collective real estate experience. Martin handles financial strategy; Lester identifies acquisition opportunities; and Larkin contributes development and municipal engagement expertise. Their insight centered on creating strategic, risk-mitigated ventures.
Orion Capital Partners serves businesses and investors, delivering sustainable, profitable commercial real estate outcomes. Its vision emphasizes enduring client relationships and exceptional results, operating with integrity, transparency, and strategic foresight. The firm leverages seasoned expertise to navigate complex markets, ensuring robust performance and long-term value creation.
Orion Equity Partners has 3 tracked investments across 2 companies. The latest tracked deal is $4.0M Series A in AnTolRx in September 2016.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2016 | AnTolRx | $4.0M Series A | Pfizer | Rivervest, JDRF |
| Feb 1, 2015 | Lysosomal Therapeutics | $20.0M Series A | Atlas Venture | Advent Life Sciences, Apollo Health Ventures, ARCH Venture Partners, Hatteras Venture Partners, Omega Funds, Polaris Partners, RED Tree Venture Capital, Roche Venture Fund, Vivo Capital, BOB Carpenter, Henri Termeer, Lilly Ventures, Partners Innovation Fund, Roche, Sanofi Ventures |
| May 1, 2014 | Lysosomal Therapeutics | $5.0M Seed | Atlas Venture | Advent Life Sciences, Apollo Health Ventures, ARCH Venture Partners, Hatteras Venture Partners, Omega Funds, Polaris Partners, RA Capital, RED Tree Venture Capital, Roche Venture Fund, Vivo Capital, Steve Hall, Reza Halse, Carole Nuechterlein, Bernard Davitian |